GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chempartner Pharmatech Co Ltd (SZSE:300149) » Definitions » 3-Year Revenue Growth Rate

Chempartner Pharmatech Co (SZSE:300149) 3-Year Revenue Growth Rate : -8.40% (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Chempartner Pharmatech Co 3-Year Revenue Growth Rate?

Chempartner Pharmatech Co's Revenue per Share for the three months ended in Mar. 2024 was ¥0.47.

During the past 12 months, Chempartner Pharmatech Co's average Revenue per Share Growth Rate was -7.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -8.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 1.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was 20.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Chempartner Pharmatech Co was 64.90% per year. The lowest was -38.80% per year. And the median was 11.90% per year.


Competitive Comparison of Chempartner Pharmatech Co's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Chempartner Pharmatech Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chempartner Pharmatech Co's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chempartner Pharmatech Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Chempartner Pharmatech Co's 3-Year Revenue Growth Rate falls into.



Chempartner Pharmatech Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Chempartner Pharmatech Co  (SZSE:300149) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Chempartner Pharmatech Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Chempartner Pharmatech Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Chempartner Pharmatech Co (SZSE:300149) Business Description

Traded in Other Exchanges
N/A
Address
No. 268 Dongfeng Middle Road, 28th Floor, Exchange Square, Yuexiu District, Guangzhou City, Guangdong, CHN, 529081
Chempartner Pharmatech Co Ltd is engaged in the research, development, production, and operation of prebiotics, micro-ecological medical, and biopharmaceuticals.
Executives
Qi Jia Hui Supervisors
Yang Xin Qiu Executives
Ceng Xian Jing Director
Xie Yong Kui Director
Zhou Xin Ping Director
Wang Cong Wei Director

Chempartner Pharmatech Co (SZSE:300149) Headlines

No Headlines